Search

everythinglearnresearchcommunity

for

Search:↓

Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Finasteride reduces Tourette syndrome symptoms, but results may be limited due to potential biases.

Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.

Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.

Thyroid receptor β can help develop new drugs to treat hair loss.

Androgens may influence bladder cancer progression by affecting cellular behavior.

Certain histamine receptors (H2R, H3R, H4R) have unique roles in treating skin diseases, with H2R helping with chronic urticaria and other conditions, H3R providing pain relief and allergy benefits, and H4R reducing inflammation and itchiness.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.

LGD1069 effectively prevents breast tumors in mice without toxicity.

TA-Ado effectively promotes hair growth and reduces hair loss.

New sulfur-containing steroid analogs show promise for more targeted medical treatments.

Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Bupropion SR may help treat trichotillomania.

A new compound was effective for imaging prostate cancer in rats.

Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.

Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.

Androgen self-administration might be controlled by membrane receptors, not nuclear ones.

Onabotulinum toxin A may help treat trichotillomania and promote hair growth.

Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.

New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.

SARMs work differently in tissues due to unique interactions and structures.

OnabotulinumtoxinA treatment improved hair-pulling disorder and hair regrowth in a woman with chronic migraines.